Overview

Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Clarity Pharmaceuticals Ltd